Your Liver's Trash Is Bilirubin Antioxidant Support

The Oasis Health Journal | Submitted July 26, 2026 | 1:31 PM EDT

By Marlo Quist · Edited by Priya Raman, C.N.C.

Your body breaks down two million red blood cells every second. The liver processes the wreckage and makes bilirubin. Bilirubin is a yellow pigment. It leaves.

Researchers measured what it does on the way out.

In two separate mouse models, animals treated with bilirubin showed improved survival compared to controls, according to a 2026 study. The bilirubin group also had lower plasma levels of neutrophil extracellular traps, which are web-like structures that white blood cells release. The traps damage surrounding tissue. Your liver's trash is bilirubin antioxidant support turned out to mean the trash tells the traps to stop.

That is not what anyone thought yesterday.

Your Liver's Trash Is Bilirubin Antioxidant Support by Stopping Neutrophils

Neutrophils are white blood cells. When they detect a threat, they can explode and release their DNA as a net to catch bacteria. This process is called NETosis. The net works. It also sticks to your own cells and kills them, which is a design flaw.

In the models, researchers found that bilirubin reduced the formation of these nets. They then tested the effect in isolated human neutrophils. Bilirubin inhibited NETosis by suppressing reactive oxygen species production and by targeting an enzyme called NOX2.

NOX2 generates the oxidative burst that neutrophils use to kill pathogens. Bilirubin promoted the internalization and degradation of NOX2 through endocytosis and autophagy. In other words, the cell ate its own weapon because bilirubin suggested it.

The bile pigment was more persuasive than expected.

What Bilirubin Antioxidant Research Actually Measured

The studies used two different mouse models: one induced by cecal ligation and puncture, the other by lipopolysaccharide injection. Both are standard experimental models. Mice are not people. The survival benefit was real in the model. The model is not the thing.

In the neutrophil experiments, researchers used cells isolated from healthy human donors and stimulated them with phorbol myristate acetate, a chemical that triggers NETosis. Bilirubin was added at concentrations within the range seen in human blood during jaundice. It reduced NET formation in a dose-dependent manner.

The effect was measurable. The cells were in a dish. A dish does not have a spleen or a prescription or a job. Antioxidant research in isolated cells tells you what can happen when you remove everything else that is happening.

The researchers also tested whether blocking endocytosis or autophagy would reverse bilirubin's effects. It did. That means bilirubin works by changing how the cell recycles NOX2, not by directly neutralizing the enzyme. It is indirect persuasion, which is how a byproduct gets things done.

Does Your Liver's Trash Is Bilirubin Antioxidant Support Work Outside the Models

The models are specific. Bilirubin reduced harm in an extreme, short-term inflammatory event. That does not establish what it does during chronic low-grade oxidative stress, which is the thing supplement shoppers are generally worried about when they search for antioxidant support.

There is related work on gasotransmitters, small molecules like nitric oxide, carbon monoxide and hydrogen sulfide. A 2026 review noted that carbon monoxide shares a pathway with bilirubin: both are produced when heme oxygenase breaks down heme. The review described these molecules as having anti-inflammatory and antioxidant effects in models of neurodegeneration, and mentioned their ability to cross the blood-brain barrier.

Bilirubin crosses too. It is lipophilic. That is a property, not a sales pitch.

The review did not test bilirubin supplementation. It discussed endogenous signaling. Your body already makes this molecule. The question is whether adding more changes the outcome or just gives your liver something to filter a second time.

What the NOX2 Finding Suggests for Cardiovascular Health

Neutrophil extracellular traps have been implicated in arterial damage. A 2026 review on albumin noted that oxidative modifications to serum proteins contribute to cardiovascular risk. Albumin and bilirubin both circulate bound to each other. Albumin carries bilirubin through the bloodstream. When albumin is oxidized, it loses some of its cargo capacity and its ability to scavenge reactive oxygen species.

The albumin review found that patients with chronic kidney disease and chronic liver disease had depleted polysulfide levels in their albumin, even when conventional oxidation markers looked normal. Polysulfide depletion impaired the protein's drug-binding and ROS-scavenging functions. Bilirubin was not the focus of that study, but it travels in the same vehicle.

If bilirubin reduces NET formation and albumin carries bilirubin, then anything that damages albumin also disrupts bilirubin transport. That is a problem with two moving parts. Supplementing one part does not fix the other. You would need the carrier and the cargo both functional, which is not something a cardiovascular support formula generally addresses.

The research shows a mechanism. It does not show that taking bilirubin in a pill replicates the mechanism.

Your Liver's Trash Is Bilirubin Antioxidant Support Studies Measured Mice and Dishes

The survival benefit was in animals. The NOX2 inhibition was in isolated cells. Those are the populations. Human trials would need to establish dosing, absorption, duration and whether bilirubin supplementation produces the same NOX2 degradation that the in vitro work demonstrated.

There are no such trials yet. Bilirubin is not available as a standalone supplement in most markets. It appears in some liver support blends as an extract from bile or as a byproduct of heme oxygenase inducers, but those formulations do not report the bilirubin content or provide pharmacokinetic data.

The molecule is endogenous. Your body makes it. It also clears it. Supplementation would need to show that raising plasma bilirubin within a safe range produces a benefit that the endogenous baseline does not. The models used exogenous bilirubin at concentrations higher than normal physiology. That worked in mice. It is not a dosing guide for a person buying a bottle.

The antioxidant research is interesting. The product research does not exist. Those are two different things, and only one of them has a price tag.

This article is education and reporting on published research. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Talk to your own clinician about your own situation.

Sources

1. Albumin as a dynamic extracellular redox regulator: from Cys34 oxidation biomarkers to polysulfide-mediated homeostatic mechanisms and clinical applications, Redox report : communications in free radical research (2026).
2. Bilirubin reduces mortality in sepsis models by inhibiting NOX2-mediated formation of neutrophil extracellular traps, Redox report : communications in free radical research (2026).
3. Unraveling the potential of gasotransmitters as neurogenic and neuroprotective molecules: focus on Alzheimer's and Parkinson's diseases, Redox report : communications in free radical research (2026).